Ireland
--:--IST
Active, not recruiting Not applicable

The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling

NCT05483738 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2020-02-01
Last updated
2025-10-02

Condition(s) studied

Mitochondrial DiseasesBone Remodeling Disorder

Investigational drug(s) / intervention(s)

Clinical assessment, blood samples, bone marrow and bone biopsy

Clinical assessment, blood samples, bone marrow and bone biopsy: Assessment of blood samples, bone marrow and bone biopsy

Study summary

Cell and mice studies suggest mitochondrial dysfunction may cause altered bone structure.

Hypothesis: Decreased mitochondrial energy production affects bone cell development and activity negatively.

Comparing humans with the mitochondrial DNA variant, m.3243A\>G, pathogenic variants in POLG or TWNK genes to healthy controls, the aim is to evaluate the effect of mitochondrial dysfunction on: 1: bone-cell development and -activity in bone marrow stem cells and blood.

2: bone cell metabolism including glucose consumption. 3: bone structure assessed by electron microscopy and μCT scans of bone biopsies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria - cases: * Genetic diagnosis with: MT-TL1 m.3243A\>G, or POLG variant, het or TWNK variant, het, \> 18 years * Signed informed consent Inclusion Criteria - controls: * Healthy subjects matched on age and gender \> 18 years * Signed informed consent Exclusion Criteria: * Renal (creatinine \> 90 µmol/l) * Liver dysfunction (AST \> 3 times the upper limit) * Medical treatment influencing bone metabolism (oral corticosteroid \<12 weeks, anti-osteoporosis treatment, sex steroids, anti-convulsants) * Pregnancy * Excessive consumption of alcohol * Treatment with anticoagulants * Pre-existing coagulopathy * Allergy to lidocaine, morphine or diazepam.

Primary outcome measure(s)

  • Extracellular acidification rate (ECAR) (mpH/min) — Up to 12 weeks
    Measurement of ECAR in human bone marrow skeletal (mesenchymal) stem cells (hBM-MSCs), osteoblasts (OB) and osteoclasts (OC)
  • Oxygen consumption rate (OCR) (mpMol/min) — Up to 12 weeks
    Measurement of OCR in hBM-MSCs, OBs and OCs
  • Growth rate (number of cells) — Up to 12 weeks
    Growth rate of of OBs and OCs

Trial sites (1)

FacilityCityRegionStatus
Dept. of Clinical Genetics Aalborg Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05483738 on ClinicalTrials.gov ↗ ← All trials in Denmark